


REMARKS

BEST AVAILABLE COPY

Applicants amend the specification for purposes of adding the priority information and amending the Title. The attached Abstract has been placed on a separate sheet of paper according to US practice and amended per the Examiner's request. Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No.

07-1392.

Respectfully submitted,


John L. Lemanowicz
Attorney for Applicants
Registration No. 37,380

Date: 23 February, 2006

Glaxo SmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8247